%0 Journal Article
%T Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study
%A Cheng-Hwai Tzeng
%A Cheng-Shyong Chang
%A Chih-Yi Hsieh
%A Ching-Yuan Kuo
%A Chinjune Lin
%A Clinton Lai
%A Darko Miljkovic
%A Jih-Luh Tang
%A Li-Yaun Bai
%A Ming-Chih Chang
%A Po-Nan Wang
%A Sheng-Fung Lin
%A Tran-Der Tan
%A Tsai-Yun Chen
%A Wen-Li Hwang
%A Yeu-Chin Chen
%J Archive of "Therapeutic Advances in Hematology".
%D 2018
%R 10.1177/2040620718756603
%X Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), is approved for the treatment of patients with chronic myeloid leukemia (CML) in many countries, including Taiwan. Though a number of controlled clinical trials have demonstrated the safety and efficacy of nilotinib, studies assessing the safety and efficacy of nilotinib in routine clinical practice are limited
%K chronic myeloid leukemia
%K clinical trial
%K imatinib-resistant
%K nilotinib
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843102/